Autonomix Medical, INC 10-K annual reports

Autonomix Medical, Inc. filed an amendment to its 2026 Annual Report to include required Part III disclosures regarding governance and executive compensation.

Autonomix Medical, Inc. filed its Form 10-K for the fiscal year ended March 31, 2026, outlining its capital stock, warrant details, and ongoing development efforts.

Autonomix Medical, Inc. filed an amendment to its annual report to provide comprehensive details on executive compensation, corporate governance, and related party transactions for the fiscal year ended March 31, 2025.

Autonomix Medical, a development-stage medical device company, reported a $50.4 million accumulated deficit and negative cash flows, raising substantial doubt about its ability to continue as a going concern, despite positive early clinical trial results for its novel nerve-sensing and ablation technology.

Autonomix Medical has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

Autonomix Medical, Inc.'s 2024 annual report highlights its development-stage status, ongoing financial challenges, and progress in its innovative neural sensing and treatment technology.